Related Experiment Videos
Medium term planning of biopharmaceutical manufacture using mathematical programming
Kais Lakhdar1, Yuhong Zhou, James Savery
1The Advanced Centre for Biochemical Engineering, Department of Biochemical Engineering, UCL University College London, Torrington Place, London WC1E 7JE, UK.
Biotechnology Progress
|October 8, 2005
Summary
Biopharmaceutical manufacturing faces capacity challenges, necessitating flexible multiproduct facilities. A new mixed integer linear program (MILP) model optimizes planning and scheduling, outperforming traditional methods for increased profitability.
Area of Science:
- Operations Research
- Biopharmaceutical Manufacturing
- Process Optimization
Background:
- Increasing regulatory pressures and capacity limitations in the biopharmaceutical sector.
- The need for flexible, cost-effective manufacturing solutions using multiproduct facilities.
- Challenges in planning and scheduling for campaign-based biopharmaceutical production.
Purpose of the Study:
- To review the complexities of planning and scheduling in biopharmaceutical manufacturing.
- To present a novel methodology for planning multiproduct biopharmaceutical manufacturing facilities.
- To develop a decision-support tool for optimizing production planning.
Main Methods:
- Formulation of the planning problem as a mixed integer linear program (MILP).
- Testing the MILP model on two representative biopharmaceutical industry planning scenarios.
- Comparison of the proposed MILP approach with an existing industrial rule-based method.
Main Results:
- The developed MILP formulation effectively represents the key decisions in multiproduct facility planning.
- The proposed methodology demonstrates superior performance compared to the industrial rule-based approach.
- Significant improvements in profitability were observed when using the MILP model.
Conclusions:
- The MILP formulation provides an effective and robust decision tool for biopharmaceutical manufacturers.
- This approach is particularly valuable for optimizing operations during periods of constrained manufacturing capacity.
- The methodology facilitates enhanced planning and scheduling for flexible, multiproduct biopharmaceutical production.